The present disclosure belongs to the technical field of polymer materials, and in particular relates to a chain extender and a preparation method and application thereof, a recyclable thermosetting polyurethane and a preparation method thereof. The present disclosure provides a chain extender whose chemical formula is shown in formula I. The chain extender provided by the present disclosure contains two types of dynamic covalent bonds, and the total number of dynamic covalent bonds is 4. The thermosetting polyurethane prepared by the provided chain extender has better hot-pressing repair efficiency. The results of the examples show that under the same hot-pressing conditions, the repair efficiency of the thermosetting polyurethane prepared by the 4,4′-dithiodianiline chain extender is 59%. The repair efficiency of thermosetting polyurethane is 97%, which is significantly improved.

The present disclosure belongs to the technical field of polymer materials, and in particular relates to a chain extender and a preparation method and application thereof, a recyclable thermosetting polyurethane and a preparation method thereof. The present disclosure provides a chain extender whose chemical formula is shown in formula I. The chain extender provided by the present disclosure contains two types of dynamic covalent bonds, and the total number of dynamic covalent bonds is 4. The thermosetting polyurethane prepared by the provided chain extender has better hot-pressing repair efficiency. The results of the examples show that under the same hot-pressing conditions, the repair efficiency of the thermosetting polyurethane prepared by the 4,4′-dithiodianiline chain extender is 59%. The repair efficiency of thermosetting polyurethane is 97%, which is significantly improved.

The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

An object of the invention is to provide a cured film which is high in sensitivity, capable of forming a pattern in a low-taper shape after development, capable of the change in pattern opening width between before and after thermal curing, an excellent in light-blocking property, and a negative photosensitive resin composition that forms the film. The negative photosensitive resin composition contains an (A) alkali-soluble resin, a (C1) photo initiator, and a (Da) black colorant, where the (A) alkali-soluble resin contains a (A1) first resin including one or more selected from the group consisting of a (A1-1) polyimide, a (A1-2) polyimide precursor, a (A1-3) polybenzoxazole, and a (A1-4) polybenzoxazole precursor, and has a structural unit having a fluorine atom at a specific ratio, and the (C1) photo initiator contains an (C1-1) oxime ester-based photo initiator that has a specific structure.

The present invention relates to a novel process for the preparation of Vortioxetine and a key intermediate thereof by employing a novel one-pot organo-pseudocatalytic C—H activation approach via hypervalent iodine chemistry.

The present invention relates to a novel process for the preparation of Vortioxetine and a key intermediate thereof by employing a novel one-pot organo-pseudocatalytic C—H activation approach via hypervalent iodine chemistry.

The present invention relates to a novel process for the preparation of Vortioxetine and a key intermediate thereof by employing a novel one-pot organo-pseudocatalytic C—H activation approach via hypervalent iodine chemistry.

The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.